Eledon Pharmaceuticals, Inc. (ELDN)
| Market Cap | 228.69M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -21.05M |
| Shares Out | 1.11M |
| EPS (ttm) | -22.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $15.99 |
| Previous Close | $16.00 |
| Change ($) | -0.01 |
| Change (%) | -0.06% |
| Day's Open | 16.10 |
| Day's Range | 15.65 - 16.14 |
| Day's Volume | 33,720 |
| 52-Week Range | 4.68 - 26.18 |
Eledon to commence trading on the Nasdaq exchange under the ticker “ELDN” effective tomorrow, January 5, 2021
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics announced the appointment of June Lee, M.D., to the company's Board of Directors.
Novus Therapeutics, Inc. (NVUS) CEO David-Alexandre Gros on Q3 2020 Results - Earnings Call Transcript
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patie...
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patie...
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis
Novus Therapeutics is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split
The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics to Present at H.C.
IRVINE, Calif. & BOSTON--(BUSINESS WIRE)--Novus Therapeutics Announces Acquisition of Anelixis Therapeutics
Novus Therapeutics (NASDAQ: NVUS) shares are trading lower on Tuesday. Ladenburg Thalmann downgraded the stock from Buy to Neutral and announced a price target of 60 cents per share.
Shares of Novus Therapeutics Inc. NVUS, -49.60% lost nearly half their value in active trading Monday, after the specialty drug maker announced disappointing trial results of its ear infection...
About ELDN
Eledon Pharmaceuticals, a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. The company's lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). It also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. The company was formerly known as Novus Therapeutics... [Read more...]
| Industry Biotechnology | Founded 2004 |
| CEO Gregory Flesher | Employees 7 |
| Stock Exchange NASDAQ | Ticker Symbol ELDN |